Aclaris scratches TSLP program from pipeline after flunking phase 2 eczema test

failure, crash, no, fail, rocket, cancelled, end
Aclaris' trial missed primary and secondary endpoints. (mrgao/iStock/Getty Images Plus)

A phase 2 study of Aclaris Therapeutics’ bosakitug in atopic dermatitis has missed its primary endpoint, adding to the setbacks anti-TSLP antibodies have encountered in the indication.

The phase 2 Admiration trial randomized 110 people with moderate-to-severe atopic dermatitis to take bosakitug, also called ATI-045, or placebo. At Week 24, the change in Eczema Area and Severity Index (EASI) score was statistically no larger on bosakitug than on placebo, causing the study to miss its primary endpoint. The trial also missed secondary endpoints. 

Admiration failed despite pharmacodynamic results showing the drug candidate engaged its target and downregulated biomarkers related to immune activation. The findings add to evidence that anti-TSLP monoclonal antibodies struggle to improve outcomes in atopic dermatitis.

Merck & Co. stopped a phase 1 trial of its TSLP asset, MK-8226, in atopic dermatitis early for business reasons in 2014. Uniquity Bio licensed the drug candidate a decade later, but none of its three mid-phase trials target atopic dermatitis. AstraZeneca and Amgen’s phase 2a trial of tezepelumab in atopic dermatitis missed its primary endpoint in 2017, prompting the companies to stop work in the indication. 

Sanofi added to the list of failures in April. While its drug candidate, lunsekimig, inhibits TSLP and IL-13, it proved no more successful than single-target assets in atopic dermatitis. In the phase 2b Velvet study, lunsekimig had no statistically significant effect on EASI, the primary endpoint, or on other measures of skin clearance. 

Last month, Aclaris linked its TSLPxIL-4Rα bispecific antibody, ATI-052, to a 45% placebo-adjusted mean change in EASI score at Day 57. However, the biotech prioritized development in eosinophilic esophagitis. The priority indication is “a less crowded opportunity” with “a more capital-efficient and fully-fundable development pathway,” Guggenheim Securities analysts said in a note to investors. 

Aclaris has removed (PDF) bosakitug from its pipeline, leaving it focused on ATI-052 and a slate of oral kinase inhibitors led by modzatinib. On Monday, the biotech disclosed the start of a phase 2b modzatinib trial in lichen planus, a T cell-driven inflammatory disease. Modzatinib inhibits ITK and JAK3. Last month, Guggenheim analysts said they are focused on modzatinib to drive Aclaris’ stock next year.

Aclaris’ shares fell 5% to $3.73 in premarket trading.